MOLECULAR DIAGNOSTICS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Molecular Diagnostics in US$ million by the following Product Segments: Infectious Disease Testing, Pharmacogenomics, and Cancer Screening. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. A six-year historic analysis is also provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. The report profiles 103 companies including many key and niche players such as -

Abbott Laboratories
Abbott Molecular
Life Technologies Corporation
Celera
Biomérieux
CytoCore Inc.


Click here to request a full list of companies covered in the report...

Code : MCP-1226
Price : $4950
Companies : 103
Pages : 572
Date : November 2012
Market Data Tables : 112

Complimentary Market Brief:


Request a Complimentary Copy of the Report Insights, Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS


 
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
Infectious Diseases Testing.....I-3
  
   Pharmacogenomics.....I-4
Cancer Screening.....I-4
  
   Global Market Outlook.....II-1
Molecular Diagnostics – A Quick Primer.....II-1
Molecular Diagnostics – The Fastest Growing Medical Diagnostic Technology.....II-1
1$100
   Key Challenges to Growth.....II-2
Current and Future analysis.....II-2
1$100
   US and Europe – Leaders in Molecular Diagnostics Adoption.....II-3
Developing Nations Offer Immense Potential.....II-3
Going Strong .....II-3
1$100
   New Applications Hold Promising Potential.....II-4
Infectious Disease Testing Drives the Diagnostics Market.....II-4
1$100
   The Future in Store.....II-51$100
   Clinical Diagnostics Industry – Trends and Tendencies.....II-6
Table 1: Worldwide In Vitro Diagnostics (IVD) Market (2010) - Market Share Breakdown by Value Sales for Roche Diagnostics, Abbott Laboratories, Siemens, J&J, Beckman Coulter, bioMerieux, and Others (includes corresponding Graph/Chart).....II-6
1$350
   Table 2: Global In-Vitro Diagnostics (IVD) Market (2010) - Value Sales (in US$ Billion) and Percentage Share Breakdown for Point of Care, Immunity Tests, Clinical Chemistry, Nucleic Acid Tests, Histology/Cytology, Microbiology, Haematology and Others (includes corresponding Graph/Chart).....II-7
Diagnostic Tests – Classification.....II-7
1$350
   Nucleic Acid Diagnostics Market – An Overview.....II-81$100
   Molecular Diagnostics – Growth Drivers.....II-91$100
   Molecular Diagnostics – A Replacement and Enabling Technology.....II-10
Molecular Diagnostics for Lymphoid Malignancies.....II-10
1$100
   Competitive Landscape.....II-11
Table 3: Worldwide Molecular Diagnostics Market (2011) - Percentage Share Breakdown by Value Sales for Roche Diagnostics, Qiagen, Abbott, Hologic (Gen-Probe), Siemens, Becton, Dickinson & Company and Others (includes corresponding Graph/Chart).....II-11
Key Players and Their Technologies.....II-11
The Top Tier.....II-11
1$350
   Mid-Sized and Small Companies.....II-12
New Entrants Eye Unmet Needs.....II-12
1$100
   Market Consolidations on the Way to Integrate in Vivo and in Vitro
  Diagnostics.....II-13
Global Molecular Diagnostics on a High Growth Curve.....II-13
Automation Driving Global Market.....II-13
Molecular Diagnostics: Marking the Convergence of Numerous Technologies.....II-13
MDx Market for Infectious Diseases Zooming Ahead.....II-13
1$100
   Aging Population, Disease Incidence – Fundamental Drivers of Growth.....II-14
Pharmaceutical Firms Carving Their Niche in Molecular Diagnostic Market.....II-14
Towards Tailoring the Right Treatment for the Right Disease.....II-14
1$100
   Limited Reimbursements by Third Party Payers – A Stumbling Block.....II-15
Disease-Specific Molecular Diagnostics to Deliver Improved Clinical Outcomes.....II-15
Molecular Diagnostics and Intellectual Property.....II-15
1$100
   Business Opportunities in the Offing.....II-16
Medical Training and Practice Challenges.....II-16
Hurdles All the Way for Companies Eyeing Molecular Diagnostics.....II-16
1$100
   Product Marketing – Key to Commercial Success.....II-17
Integration of Molecular Diagnostics into Therapeutics.....II-17
1$100
   Molecular Diagnostics – Moving from Centralization to Decentralization.....II-18
Migrating to Decentralized Format.....II-18
Going Ahead with Decentralization.....II-18
2$125
   Molecular Diagnostics – Definition & Scope.....II-20
Molecular Diagnostics – Impact on Healthcare.....II-20
1$100
   Utility of Molecular Diagnostic Tests.....II-21
Background of Molecular Diagnostics.....II-21
Major Molecular Diagnostics Products.....II-21
1$100
   Major Test Launches in Molecular Diagnostics in the Recent Past.....II-22
Unabated Developments in Molecular Diagnostics Technology.....II-22
Signal Amplification Technologies.....II-22
PCR – New Developments.....II-22
1$100
   Major Applications of Real-Time PCR.....II-23
Quantitative Real-Time PCR for Molecular Diagnostics.....II-23
Signal Detection and Quantification.....II-23
1$100
   Quantitative Real-Time RT-PCR Analysis.....II-24
Applications of Quantitative Real-Time PCR Analysis.....II-24
Viral Detection and Viral-Load Monitoring.....II-24
Sensitive Detection of Infectious Disease Agents.....II-24
Predisposition Testing.....II-24
Non-PCR Methods.....II-24
Other Signal Amplification Technologies.....II-24
DNA Probe Based Products.....II-24
1$100
   Direct Detection of Specific Nucleic Acid Sequences.....II-25
Nucleic Acid Amplification and Detection.....II-25
1$100
   DNA Sequencing and Gene Detection.....II-26
Arrays of Immobilized Probes (DNA Chips) in Gene Detection.....II-26
RNA Diagnostics.....II-26
1$100
   Complementary Molecular Diagnostic Technologies.....II-27
Fluorescent In-Situ Hybridization (FISH).....II-27
DNA Biochips / Microarrays.....II-27
1$100
   Biosensors.....II-281$100
   Proteomic Technologies for Molecular Diagnostics.....II-29
Nanotechnology for Molecular Diagnostics.....II-29
Technologies on the Anvil.....II-29
Haplotype Analysis – A Distant Possibility.....II-29
1$100
   Chronic Multi-Gene Defects Now Diagnosable.....II-301$100
   Infectious Diseases Testing.....II-31
Activity in the Field.....II-31
1$100
   Identifying Multidrug Resistance.....II-32
Infectious Disease Treatment Monitoring.....II-32
Other Infectious Diseases Applications.....II-32
Genetic Disease Testing Applications.....II-32
1$100
   Pharmacogenomics – Prognosis Based on Genomics.....II-33
Cancer Screening & Diagnosis.....II-33
1$100
   Molecular Tests Lead the Way for Cancer IVD Market Growth.....II-341$100
   Other Testing Applications.....II-351$100
   Trovagene Acquires MultiGEN's Clinical Laboratory Assets.....II-36
Qiagen Acquires Intelligent Bio-Systems.....II-36
Siemens Inks Agreements with Tocagen and ViiV Healthcare to Develop Companion
  Tests.....II-36
HTG Molecular Diagnostics Collaborates with Sanofi US.....II-36
1$100
   DaAn Gene and Life Technologies Form Joint Venture.....II-37
Exosome Diagnostics and Life Technologies Ink Agreement.....II-37
1$100
   GE Healthcare Acquires SeqWright.....II-38
Phthisis Diagnostics Expands its Distribution Network.....II-38
1$100
   Luminex to Acquire GenturaDx.....II-39
Phthisis Diagnostics Inks Distribution Agreement with Genetix Biotech Asia.....II-39
1$100
   Life Technologies Acquires Navigenics.....II-40
Abbott to Join Forces with Merck.....II-40
1$100
   Signal Genetics to Acquire ChipDX LLC.....II-41
Quest Diagnostics Acquires S.E.D. Medical Laboratories.....II-41
Hologic Acquires Gen-Probe.....II-41
1$100
   Accelerate Brain Cancer Cure Joins Hands with Exosome Diagnostics.....II-42
QIAGEN Collaborates with Cardinal Health.....II-42
LabCorp Acquires MEDTOX.....II-42
1$100
   Genzyme Inks Agreement with Veracyte to Market Afirma Thyroid FNA Analysis
  Solution.....II-43
Celera Enters into Distribution Agreement with Abbott.....II-43
Sanofi-Aventis Acquires Genzyme.....II-43
Genzyme Divests Diagnostic Products Business to Sekisui Chemical.....II-43
1$100
   Fortis Healthcare's Offshore Subsidiary Acquires Controlling Stake in RadLink.....II-44
Agilent Technologies Inks Partnership Agreement with Integrated Diagnostics.....II-44
Genzyme to Divest Pharmaceutical Intermediates Business to ICIG's Affiliate.....II-44
1$100
   Hologic Acquires Interlace Medical.....II-45
Applied BioCode Inks License and Supply Agreement with Hologic.....II-45
WuXi AppTec Partners with Qiagen.....II-45
1$100
   OCM Acquisition Takes over Orchid Cellmark.....II-46
Modern Mobility Aids to Take Over LumiGene Technologies.....II-46
AmerisourceBergen Takes over Premier Source.....II-46
1$100
   QIAGEN Acquires Cellestis.....II-47
QIAGEN Signs Agreement to Acquire Majority Interest in Ipsogen.....II-47
Novartis to Acquire Genoptix.....II-47
Vermillion Concludes Purchase of Correlogic’s Ovarian Cancer Diagnostics
  Business.....II-47
1$100
   VitaPath Genetics and Alere Enter into Strategic Partnership for Molecular
  Diagnostics.....II-48
Mingyuan Medicare to Purchase 70% Stake in Yuangi Bio.....II-48
Quest Diagnostics Acquires Athena Diagnostics.....II-48
1$100
   Luminex Takes Over Eragen Biosciences.....II-49
Life Technologies Enters into Distribution Commercial Agreement for Quidel
  Assays.....II-49
BD and Diagenode Announce Agreement.....II-49
1$100
   Gamma-Dynacare Buys Warnex Medical Laboratories.....II-50
OraSure Technologies to Takeover DNA Genotek.....II-50
1$100
   Hologic Takes Over TCT International.....II-51
Affymetrix to Purchase eBioscience.....II-51
Sequenom Enters into Licensing Partnership with LifeCodexx.....II-51
1$100
   LABSCO Inks Agreement with Cepheid.....II-52
Abbott to Expand GSK Agreement for Cancer Companion Diagnostic Test.....II-52
IntegenX Signs Distribution Agreement with Promega for RapidHIT Human Identification
  System.....II-52
1$100
   BD Diagnostics Partners with Biodiversity for BD MAX Molecular Diagnostic
  Assays.....II-53
bioMérieux Acquires ARGENE.....II-53
1$100
   Caliper Partners with Seegene to Expand Diagnostic Tests.....II-54
Enzo Clinical Labs Enters into Agreement with IncellDx.....II-54
1$100
   Akonni and Seegene Ink Licensing Agreement.....II-55
Tecan Signs OEM Agreement with Major Diagnostics Company.....II-55
Tecan Inks License and Collaboration Agreement with Enigma.....II-55
Myriad Genetics Secures Option to Buy Crescendo Bioscience.....II-55
1$100
   PerkinElmer Takes Over chemagen Biopolymer- Technologie AG.....II-56
Mayo Clinic Enters into Agreement with Rheonix.....II-56
1$100
   Qiagen and Epigenomics Ink Option Agreement.....II-571$100
   ExonHit Therapeutics to Acquire RedPath Integrated Pathology.....II-58
Life Technologies Acquires AcroMetrix of Benicia.....II-58
Bar Harbor BioTechnology Establishes New Division.....II-58
SIRS-Lab Partners with Analytik Jena.....II-58
1$100
   QIAGEN Enters into a Partnership with Genome Diagnostics.....II-59
IncellDx Enters into Supply Contract with Accuri.....II-59
BioMerieux Partners with Knome.....II-59
1$100
   Caliper Enters into an Agreement with Access Genetics.....II-60
Debiopharm Group Forms Partnership with Biocartis.....II-60
AdnaGen AG Enters into a Contract with TATAA Molecular Diagnostics.....II-60
1$100
   Roche Diagnostics Enters into Partnership with CapitalBio.....II-61
Epigenomics Signs Distribution Agreement with Epi proColon.....II-61
Genomic Health Selects IDBS to Provide Tools for Clinical Research.....II-61
TriLink BioTechnologies Signs Agreement with Biofortuna.....II-61
1$100
   Pathwork Diagnostics Enters into Partnership with Novartis.....II-62
Affymetrix Signs Agreement with Signature Diagnostics.....II-62
Knome and bioMerieux Ink Exclusive Strategic Agreement.....II-62
1$100
   GenMark Receives License to Innogenetics HCV Genotyping Patent.....II-63
GE Healthcare Takes Over Clarient.....II-63
Cypress to Sell Diagnostics Unit to Exagen.....II-63
1$100
   EB Analytics Acquires EnviroLogix.....II-64
IRIS Takes over AlliedPath.....II-64
bioMerieux Takes Over Selected Assets of AnagnosTec.....II-64
Hologic Takes Over Sentinelle Medical.....II-64
1$100
   Gen-Probe Takes Over GTI Diagnostics.....II-65
LabCorp Takes Over Genzyme Genetics.....II-65
1$100
   bioMérieux Inks Agreement with Biocartis.....II-66
Genzyme Sells Genzyme Genetics to LabCorp.....II-66
Life Technologies Obtains IVD Marking for 7500 Fast Dx PCR Instrument.....II-66
1$100
   Xenomics Changes Name to TrovaGene.....II-67
Abbott and GSK Team Up in the Area of Molecular Diagnosis.....II-67
Asuragen Enters Into Collaborations for Pancreatic Cancer Tests.....II-67
Transgenomic Licenses Intellectual Property from Integragen.....II-67
1$100
   Health Discovery Inks Agreement with Pancreas, Biliary and Liver Surgery Center of New
  York.....II-68
Qiagen Enters into Agreement with Celera.....II-68
The Tecan Group Inks Agreement with Enigma.....II-68
1$100
   Northeast Pharmaceuticals to Establish Biopharma JV with Shenyang.....II-69
Wescor Divests Microarray Technology Related Assets to Gamida For Life Group.....II-69
Predictive Biosciences Takes Over OncoDiagnostic Laboratory.....II-69
1$100
   Applied Biosystems Obtains Approval for AmpFlSTR® MiniFiler™ PCR Amplification
  Kit.....II-70
Life Technologies Acquires AcroMetrix.....II-70
Ipsogen SA and The Institut Curie Enters into Scientific Collaboration
  Agreement.....II-70
bioTheranostics and Ferrer inCode Enters into Commercial Agreement.....II-70
1$100
   Quidel Corp Signs Definitive Agreement to Purchase Diagnostic Hybrids.....II-71
Abbott Obtains CE Marking for New Diagnostic Test.....II-71
Transgenomic Enters into Licensing Agreement with Gene Solutions.....II-71
1$100
   QIAGEN Acquires SABiosciences.....II-72
Corgenix Medical and BG Medicine Inks Supply Agreement.....II-72
Roche receives FDA Approval for Additional Usage of cobas® TaqScreen MPX Test.....II-72
1$100
   Gen-Probe Obtains FDA Approval for Marketing of ProParaflu+TM Assay.....II-73
bioMerieux Enters into Agreement with GSK.....II-73
Tecan Group and Hologic Sign Agreement.....II-73
1$100
   QIAGEN Takes Over DxS.....II-74
Tyrian Ends Partnership with Becton, Dickinson and Co.....II-74
Becton, Dickinson and Co to Purchase HandyLab.....II-74
1$100
   Quidel and BioHelix Enter into Agreement.....II-75
Gen-Probe to Take Over Prodesse.....II-75
Summit Partners Acquires Stake in ApoCell.....II-75
Merck to form Alliance with QIAGEN.....II-75
1$100
   Gen-Probe to Spin Off Industrial Testing Assets.....II-76
ImClone Systems and Bristol-Myers Squibb Enter into Collaboration with DxS.....II-76
Danaher to Acquire A Joint Venture Company.....II-76
1$100
   Abbott Enters into Alliance with Pfizer for Molecular Diagnostic Test.....II-77
Rosetta and Warnex Ink Distribution Agreement.....II-77
ViraCor Laboratories Merges with IBT Laboratories.....II-77
ELITech Takes Over Assets of Nanogen.....II-77
1$100
   LabCorp Signs Definitive Agreement with Monogram Biosciences.....II-78
Axial Biotech and University of Utah Enter into Collaboration.....II-78
Celera and Bayer Schering Pharma Sign Licensing Agreement.....II-78
1$100
   AVESTHAGEN Enters into Collaboration with VTT Technical Research Centre.....II-79
3M Terminates Collaboration Agreement with Gen-Probe.....II-79
BioGenex and Abbott Expand Joint Development and Distribution Agreement.....II-79
1$100
   Pfizer Extends Collaboration Agreement with Monogram Biosciences.....II-80
BD Diagnostics Inks Agreement with HandyLab.....II-80
TriLink BioTechnologies and Osmetech Molecular Diagnostics Ink Agreement.....II-80
1$100
   PerkinElmer Buys Analytica of Branford.....II-81
Ipsogen Signs Agreement with Arup Laboratories.....II-81
Prometheus Laboratories and Rosetta Genomics Ink Agreement.....II-81
AMDL and Precision Diagnostic Laboratory Signs Agreement.....II-81
1$100
   Osmetech Signs Agreement with Fisher HealthCare.....II-82
Interleukin Genetics Inks Licensing Agreement with LABEC Pharma.....II-82
deCODE Genetics Inks Licensing Agreements with Celera.....II-82
1$100
   Nuvera Biosciences Signs Licensing Agreement with Veridex.....II-83
GE Healthcare Inks Research Agreement with Brigham and Women's Hospital.....II-83
Gen-Probe Purchases Tepnel Life Sciences.....II-83
AdnaGen AG Receives US Patent.....II-83
Agilent Technologies Selects Asuragen as Certified Service Provider.....II-83
1$100
   Genstruct Enters into Partnership with Gene Logic.....II-84
Lab21 Takes Over Biotec Laboratories.....II-84
ProGenTech and Innovative Biosensors Jointly Sign Extension Agreement.....II-84
1$100
   Nanogen Signs and Scandinavian Gene Synthesis Inks Agreement.....II-85
Health Discovery Corporation Inks Licensing Agreement with Abbott.....II-85
BD Diagnostics Receives CE Marking for Amplified DNA Assays.....II-85
1$100
   Transgenomic Signs Licensing Agreement Power3 Medical Products.....II-86
Rubicon Genomics and Abbott Enter into Licensing Agreement.....II-86
Novartis Extends Collaboration with Gen-Probe.....II-86
1$100
   Eurogentec Receives ISO-Certification for IVD Oligonucleotides.....II-87
Dako and OSI Pharmaceuticals Enter into Collaboration.....II-87
Combimatrix Molecular Diagnostics and Lenetix Enter into Partnership.....II-87
Sequenom to Acquire AttoSense™ Tests of SensiGen.....II-87
1$100
   Epigenomics AG and Sysmex Ink Research and Development Collaboration Deal.....II-88
Gene Express and Biogenuix Medsystems Signs Distribution Agreement.....II-88
1$100
   Gene Express and Funakoshi Enter into Distribution Agreement.....II-89
BD and Company Obtains FDA Approval for Marketing GeneOhm™ Cdiff Test.....II-89
XDx and Bristol-Myers Squibb Company Signs Collaborative Agreement.....II-89
1$100
   Rosetta Genomics and Teva Pharmaceutical Industries Signs Distribution
  Agreement.....II-90
1$100
   Quest Diagnostics Introduces Cervical Cancer TERC Test.....II-91
BD Diagnostics Introduces Range of Open System Extraction and Master Mix Kits.....II-91
1$100
   Pro-Lab Diagnostics Launches Portrait Analyser.....II-92
Quest Diagnostics Introduces Molecular Tests for Thyroid Cancer.....II-92
Seegene to Launch Quantitative TOCE Highly Multiplexed Quantitative Real-Time
  Molecular Technology.....II-92
1$100
   ELITech Molecular Diagnostics Unveils 2nd Generation MRSA/SA ELITe MGB® Kit.....II-93
MDxHealth Introduces ConfirmMDx™ for Prostate Cancer Test.....II-93
1$100
   Ipsos Healthcare Unveils Molecular Diagnostic Monitor Line.....II-94
Seegene Launches Anyplex™ MDR-TB Test.....II-94
Berg Diagnostics Introduces Molecular Diagnostics Offerings.....II-94
1$100
   Life Technologies Unveils VetMAX™-Gold SIV Detection Kit.....II-95
Life Technologies Obtains Chinese Approval for Applied Biosystems 3500 Dx / 3500xL
  Dx Genetic Analyzer.....II-95
1$100
   LabCorp Launches HCV GenoSure NS3/4A.....II-96
Quest Diagnostics Launches AccuType IL28B Test.....II-96
Quest Diagnostics Unveils Simplexa™ Direct Test.....II-96
Quest Diagnostics Unveils Simplexa™ Dengue Test.....II-96
2$125
   Quest Diagnostics Unveils Molecular Blood Test.....II-98
LabCorp Unveils IL-28B Test.....II-98
Gen-Probe Unveils ELUCIGENE™ KRAS.BRAF Kit.....II-98
1$100
   QIAGEN Unveils QIAsymphony RGQ System.....II-99
Gen-Probe Unveils PANTHER™ System.....II-99
Life Technologies Unveils ViralSEQ™ Vesivirus Detection Kit.....II-99
1$100
   Applied Biosystems New Forensic DNA Kits.....II-100
Quest Diagnostics Launches ColoVantage™ Test.....II-100
QIAGEN Introduces CE-labeled KRAS Kit.....II-100
1$100
   Roche Introduces Cobas 4800.....II-101
bioMérieux Launches Upgraded Version of NucliSENS EasyQ® Influenza A/B Test.....II-101
bioMérieux Introduces NucliSENS EasyQ® MRSA.....II-101
1$100
   Roche Launches AMPLILINK 3.3 Series Software and cobas p 630 Instrument.....II-102
Applied Biosystems Unveils 3500 Series and 3500 DX Series Genetic Analyzer.....II-102
1$100
   Prometheus Laboratories Introduces New Range of Cancer Diagnostic Products.....II-103
Sequenom Introduces SensiGene Cystic Fibrosis Carrier Screening Test.....II-103
Triplex and MedMira to Unveil New Rapid Tests.....II-103
1$100
   Applied Biosystems to Introduce New Range of TaqMan® PCR Assays.....II-104
Quest Diagnostics Unveils HIV-1 Coreceptor Tropism Test.....II-104
Luminex introduced New Range of Cystic Fibrosis Tests.....II-104
1$100
   bioMérieux Introduces VIDAS® EBV Test.....II-105
Luminex Unveils Two Novel Cystic Fibrosis Tests.....II-105
MEDomics Launches MitoDx™ for Diagnosing Mitochondrial Diseases.....II-105
1$100
   Exagen Diagnostics Unveils eXaIBStest and eXaIBD Blood Tests.....II-106
bioMérieux Introduces NucliSENS EasyQ® HIV-1 v2.0 Test.....II-106
PreAnalytiX Introduces PAXgene® Blood miRNA Kit.....II-106
ViraCor Laboratories Introduces New JCV Test.....II-106
1$100
   ViraCor Laboratories Rolls Out JC Virus Detection Test.....II-107
Focus Diagnostics Laboratory Introduces PCR Test.....II-107
Siemens Launches CLINITEK AUWi Urine Analyzing System.....II-107
1$100
   Ocimum Biosolutions to Introduce New H1N1 Virus Detection Test.....II-108
Myriad Genetics Introduces OnDose for Cancer Diagnosis.....II-108
Applied Biosystems Introduces TaqMan® Array Gene Signature Plates.....II-108
1$100
   GeneNews to Develop Blood-Based Diagnostic Tests.....II-109
Seegene Rolls Out Seeplex® Diarrhea ACE Detection Test.....II-109
Seegene Unveils Seeplex® Meningitis ACE Detection test.....II-109
1$100
   Cepheid Introduces Xpert MRSA/SA Nasal Diagnostic Test.....II-110
Roche to Launch LightCycler Test.....II-110
Xenomics Unveils New Technology for Analyzing in Vivo Cell Death.....II-110
1$100
   bioMerieux Unveils NucliSENS EasyQ® HPV Molecular Analytical Test.....II-111
Xenomics to Introduce Innovative Gender Prediction Test.....II-111
Evogen Unveils New EvoCycler™ HD12 Molecular Diagnostics System.....II-111
1$100
   Siemens Healthcare Launches Innovance Antithrombin Test.....II-112
Rosetta Genomics Launches miRview™ meso Diagnostic Test.....II-112
ViraCor Laboratories Introduces Cytomegalovirus Antiviral Resistance Test.....II-112
1$100
   Abbott Launches Diagnostic Test for HPV Detection.....II-113
Pathwork Diagnostics Introduces Tissue of Origin Test.....II-113
1$100
   Evogen to Offer Diagnostic Tests.....II-1141$100
   Abbott Laboratories (US).....II-115
Abbott Molecular (US).....II-115
Life Technologies Corporation (US).....II-115
1$100
   Celera (US).....II-116
bioMérieux (France).....II-116
1$100
   CytoCore Inc. (US).....II-117
ELITech Group (France).....II-117
GE Healthcare (US).....II-117
1$100
   Genzyme Corp. (US).....II-118
Hologic, Inc. (US).....II-118
1$100
   Laboratory Corporation of America® Holdings (US).....II-119
MiraiBio, Inc. (US).....II-119
1$100
   Novartis Diagnostics (US).....II-120
QIAGEN N.V (The Netherlands).....II-120
1$100
   Quest Diagnostics, Inc. (US).....II-121
Roche Diagnostics (Switzerland).....II-121
Siemens Healthcare Diagnostics Inc. (US).....II-121
1$100
   Tecan Group Ltd. (Switzerland).....II-1221$100
   Table 4: World Recent Past, Current & Future Market Analysis for Molecular Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart).....II-1231$350
   Table 5: World Historic Review for Molecular Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart).....II-1241$350
   Table 6: World 15-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart).....II-1251$350
   Molecular Diagnostics Market by Application.....II-126
Table 7: World Recent Past, Current & Future Market Analysis for Molecular Diagnostics (Infectious Disease Testing) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart).....II-126
1$350
   Table 8: World Historic Review for Molecular Diagnostics (Infectious Disease Testing) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart).....II-1271$350
   Table 9: World 15-Year Perspective for Molecular Diagnostics (Infectious Disease Testing) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart).....II-1281$350
   Table 10: World Recent Past, Current & Future Market Analysis for Molecular Diagnostics (Pharmacogenomics) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart).....II-1291$350
   Table 11: World Historic Review for Molecular Diagnostics (Pharmacogenomics) by Geographic Region - The US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart).....II-1301$350
   Table 12: World 15-Year Perspective for Molecular Diagnostics (Pharmacogenomics) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart).....II-1311$350
   Table 13: World Recent Past, Current & Future Market Analysis for Molecular Diagnostics (Cancer Screening) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart).....II-1321$350
   Table 14: World Historic Review for Molecular Diagnostics (Cancer Screening) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart).....II-1331$350
   Table 15: World 15-Year Perspective for Molecular Diagnostics (Cancer Screening) by Geographic Region - Percentage Breakdown of Dollar Sales for the US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart).....II-1341$350
   A. Market Analysis.....III-1
Current and Future Analysis.....III-1
A Precursor to the Molecular Diagnostics Market in the US.....III-1
US Diagnostic Market: An Overview.....III-1
Molecular Diagnostics Heavily Tied to Proteomics and Genomics.....III-1
1$75
   Burgeoning Potential for Genetic Testing.....III-2
Regulatory Environment.....III-2
Regulations Out for Molecular Diagnostic Testing of HPV.....III-2
1$75
   Limited Reimbursements – A Major Hindrance.....III-3
Strategic Corporate Developments.....III-3
17$375
   Product Launches.....III-203$125
   Key players.....III-236$150
   B. Market Analytics.....III-29
Table 16: US Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart).....III-29
1$200
   Table 17: US Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart).....III-301$200
   Table 18: US 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for Years 2004, 2011 & 2018 (includes corresponding Graph/Chart).....III-311$200
   A. Market Analysis.....III-32
Current and Future Analysis.....III-32
Strategic Corporate Development.....III-32
1$75
   B. Market Analytics.....III-33
Table 19: Canadian Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart).....III-33
1$200
   Table 20: Canadian Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart).....III-341$200
   Table 21: Canadian 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart).....III-351$200
   A. Market Analysis.....III-36
Current and Future Analysis.....III-36
1$75
   B. Market Analytics.....III-37
Table 22: Japanese Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart).....III-37
1$200
   Table 23: Japanese Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart).....III-381$200
   Table 24: Japanese 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart).....III-391$200
   A. Market Analysis.....III-40
Current and Future Analysis.....III-40
Insight into Molecular Diagnostics Markets in Europe.....III-40
1$75
   Table 25: European IVD Market for Select Countries (2010) - Market Value in US$ Million for Spain, UK, Germany, Italy, France, Poland, Netherlands, Belgium, Denmark, Portugal, Austria, Sweden, Bulgaria and Lithuania (includes corresponding Graph/Chart).....III-411$200
   B. Market Analytics.....III-42
Table 26: European Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart).....III-42
1$200
   Table 27: European Historic Review for Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart).....III-431$200
   Table 28: European 15-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, and Rest of Europe Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart).....III-441$200
   Table 29: European Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart).....III-451$200
   Table 30: European Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart).....III-461$200
   Table 31: European 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics and Cancer Screening Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart).....III-471$200
   A. Market Analysis.....III-48
Current and Future Analysis.....III-48
Strategic Corporate Developments.....III-48
1$75
   Product Launch.....III-49
Key players.....III-49
2$125
   B. Market Analytics.....III-51
Table 32: French Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart).....III-51
1$200
   Table 33: French Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart).....III-521$200
   Table 34: French 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart).....III-531$200
   A. Market Analysis.....III-54
Current and Future Analysis.....III-54
Overview.....III-54
1$75
   Table 35: German Market for Laboratory Product (2010) - Market Value (in US$ Million) and Percentage Share for Clinical Chemistry Reagents, Immunochemistry Reagents, Hematology, Infectious Immunology, Consumables/Instruments, Microbiology Reagents and Services/Spare Parts (includes corresponding Graph/Chart).....III-55
Strategic Corporate Development.....III-55
1$200
   B. Market Analytics.....III-56
Table 36: German Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart).....III-56
1$200
   Table 37: German Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart).....III-571$200
   Table 38: German 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart).....III-581$200
   A. Market Analysis.....III-59
Current and Future Analysis.....III-59
1$75
   B. Market Analytics.....III-60
Table 39: Italian Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart).....III-60
1$200
   Table 40: Italian Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart).....III-611$200
   Table 41: Italian 15Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart).....III-621$200
   A. Market Analysis.....III-63
Current and Future Analysis.....III-63
Strategic Corporate Development.....III-63
Product Launch.....III-63
1$75
   B. Market Analytics.....III-64
Table 42: The UK Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart).....III-64
1$200
   Table 43: The UK Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart).....III-651$200
   Table 44: The UK 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart).....III-661$200
   A. Market Analysis.....III-67
Current and Future Analysis.....III-67
Strategic Corporate Developments.....III-67
3$125
   Product Launches.....III-70
Key players.....III-70
2$100
   B. Market Analytics.....III-72
Table 45: Rest of European Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart).....III-72
1$200
   Table 46: Rest of European Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart).....III-731$200
   Table 47: Rest of European 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for 2004, 2011 and 2018 (includes corresponding Graph/Chart).....III-741$200
   A. Market Analysis.....III-75
Current and Future Analysis.....III-75
Diagnostic Market in India.....III-75
1$75
   Key Statistics.....III-76
Table 48: Leading Players in the Chinese IVD Market (2010) - Percentage Share Breakdown of Value Sales for Roche, Beckman/Danaher, Abbott, Siemens, Symex, Mindray, Hitachi, bioMerieux, J&J, DAAN and Others (includes corresponding Graph/Chart).....III-76
Strategic Corporate Developments.....III-76
1$200
   Product Launches.....III-772$100
   B. Market Analytics.....III-79
Table 49: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart).....III-79
1$200
   Table 50: Asia-Pacific Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart).....III-801$200
   Table 51: Asia-Pacific 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart).....III-811$200
   A. Market Analysis.....III-82
Current and Future Analysis.....III-82
Product Launches.....III-82
1$75
   B. Market Analytics.....III-83
Table 52: Rest of World Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart).....III-83
1$200
   Table 53: Rest of World Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart).....III-841$200
   Table 54: Rest of World 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics and Cancer Screening Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart).....III-851$200
  
Total Companies Profiled: 103 (including Divisions/Subsidiaries - 121)

Region/Country Players

The United States 85 Canada 4 Japan 1 Europe 23 France 5 Germany 5 The United Kingdom 4 Rest of Europe 9 Asia-Pacific (Excluding Japan) 7 Middle East 1
Click here to request a full table of contents and more details on this project.